Immunotherapy leverages the body’s immune system to identify and attack cancer cells. By enhancing the immune system's ability to recognize and fight cancer, this treatment has achieved remarkable success, particularly in advanced melanoma and lung cancer. For many patients, immunotherapy has led to long-lasting remissions, even in cases once deemed incurable. At UVM, we proudly provide a full range of approved immunotherapies tailored to individual needs. 

Targeted therapies focus on specific genetic mutations or proteins that drive cancer growth. Focusing on a tumor's unique biology makes these treatments more precise and often have fewer side effects than traditional chemotherapy. For instance, targeted therapies for HER2-positive breast cancer or lung cancers with mutations like EGFR or ALK have transformed the outcomes of many patients. A key component of this personalized approach is genomic testing, which identifies the genetic changes driving a patient’s cancer. This information enables oncologists to select treatments most likely to work for that individual. For many, genomic testing has unlocked the door to therapies that extend life and improve its quality. 

Unlike chemotherapy, which can affect all rapidly dividing cells and lead to significant side effects, immunotherapy, and targeted therapies are more selective. These advances offer better tolerability and an improved quality of life, giving patients and their families renewed hope. Together, these approaches are reshaping the future of cancer care, providing more effective and personalized options than ever before.